Cash Flow Statement
Growth Metrics

Mimedx (MDXG) Total Non-Current Liabilities (2010 - 2026)

Mimedx recorded quarterly Total Non-Current Liabilities of $60.6 million in Q1 2026, down 24.88% quarter-over-quarter from $80.7 million in Q4 2025, and up 0.82% year-over-year from $60.2 million in Q1 2025.

Mimedx's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $60.6 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 0.82% year-over-year to $60.6 million; the TTM figure through Mar 2026 stood at $60.6 million (up 0.82% YoY), while the FY2025 annual figure was $80.7 million, up 27.29% from the prior year.
  • Total Non-Current Liabilities came in at $60.6 million for Q1 2026 at Mimedx, down from $80.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $94.3 million in Q3 2022 to a low of $58.3 million in Q2 2024.
  • A 5-year average of $77.2 million and a median of $80.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities sank 37.55% in 2024 and advanced 27.29% in 2025, its largest moves.
  • Mimedx's Total Non-Current Liabilities stood at $92.2 million in 2022, then increased by 2.12% to $94.1 million in 2023, then slumped by 32.6% to $63.4 million in 2024, then gained by 27.29% to $80.7 million in 2025, then fell by 24.88% to $60.6 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $60.6 million, $80.7 million, and $74.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn 60.64 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 60.64 Mn
Dec 31, 2025 80.73 Mn
Sep 30, 2025 74.52 Mn
Jun 30, 2025 67.50 Mn
Mar 31, 2025 60.15 Mn
Dec 31, 2024 63.43 Mn
Sep 30, 2024 59.96 Mn
Jun 30, 2024 58.26 Mn
Mar 31, 2024 60.67 Mn
Dec 31, 2023 94.11 Mn
Sep 30, 2023 92.59 Mn
Jun 30, 2023 93.30 Mn
Mar 31, 2023 89.58 Mn
Dec 31, 2022 92.15 Mn
Sep 30, 2022 94.33 Mn
Jun 30, 2022 85.49 Mn
Mar 31, 2022 84.83 Mn
Dec 31, 2021 90.48 Mn
Sep 30, 2021 89.76 Mn
Jun 30, 2021 98.48 Mn
Mar 31, 2021 103.21 Mn
Dec 31, 2020 106.86 Mn
Sep 30, 2020 104.92 Mn
Jun 30, 2020 125.14 Mn
Mar 31, 2020 125.34 Mn
Dec 31, 2019 129.23 Mn
Sep 30, 2019 135.54 Mn
Jun 30, 2019 141.17 Mn
Mar 31, 2019 64.35 Mn
Dec 31, 2018 71.55 Mn
Dec 31, 2017 45.81 Mn
Sep 30, 2017 36.24 Mn
Jun 30, 2017 51.51 Mn
Mar 31, 2017 58.37 Mn
Dec 31, 2016 68.33 Mn
Sep 30, 2016 57.56 Mn
Jun 30, 2016 39.47 Mn
Mar 31, 2016 29.74 Mn
Dec 31, 2015 27.93 Mn
Sep 30, 2015 24.35 Mn
Jun 30, 2015 19.46 Mn
Mar 31, 2015 18.46 Mn
Dec 31, 2014 18.40 Mn
Sep 30, 2014 14.45 Mn
Jun 30, 2014 9.91 Mn
Mar 31, 2014 9.59 Mn
Dec 31, 2013 9.61 Mn
Sep 30, 2013 8.33 Mn
Jun 30, 2013 6.14 Mn
Mar 31, 2013 5.97 Mn
Dec 31, 2012 14.82 Mn
Sep 30, 2012 14.04 Mn
Jun 30, 2012 11.48 Mn
Mar 31, 2012 14.04 Mn
Dec 31, 2011 14.89 Mn
Sep 30, 2011 11.65 Mn
Jun 30, 2011 11.33 Mn
Dec 31, 2010 1.25 Mn